Clinical trials: Relapsed and Refractory Multiple Myeloma
Multiple Myeloma
Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma
To assess if amrubicin is safe and useful for patients with multiple myeloma requiring additional treatment.
- Trial name
- NCT01355705
- Testing
- Amrubicin, Lenalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Michaela Liedtke
Lymphoma, Multiple Myeloma
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
The purpose of the study is to determine whether the addition of Elotuzumab to Lenalidomide/low-dose Dexamethasone will increase the progression free survival (PFS).
- Trial name
- ELOQUENT - 2 (NCT01239797)
- Testing
- Lenalidomide, Dexamethasone, Dexamethasone (Oral)
- Where
- 216 sites in United States, Australia and 21 more
- Volunteers
- 646 people
- Sponsor
- Bristol-Myers Squibb
Refractory Multiple Myeloma, Multiple Myeloma in Relapse
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
This is a registration, open-label phase 1 study of the combination of ibrutinib/lenalidomide:/dexamethasone in women and men with relapsed/refractory multiple myeloma.
- Conditions
- Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma
- Trial name
- NCT03702725
- Testing
- Ibrutinib, Lenalidomide, Dexamethasone
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Alliance Foundation Trials, LLC.
Multiple Myeloma
A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma
Study PT-112-102, a multicenter, open-label dose-finding and pharmacokinetic study of PT-112 in patients with relapsed or refractory multiple myeloma. This is designed as a two-part study.
- Trial name
- NCT03288480
- Testing
- PT-112
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Promontory Therapeutics Inc.
Multiple Myeloma, Relapsed/Refractory
Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma
To evaluate the safety and tolerability of chimeric antigen receptor gene-modified T cells targeting BCMA for the treatment of relapsed/refractory multiple myeloma
- Trial name
- NCT06581640
- Testing
- CAR-T treatment
- Where
- China
- Volunteers
- 5 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Refractory Plasma Cell Myeloma
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase II trial studies how well paclitaxel albumin-stabilized nanoparticle formulation works in treating patients with multiple myeloma that has returned or did not respond to treatment.
- Trial name
- NCT01646762
- Testing
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients
- Trial name
- NCT05972135
- Testing
- Teclistamab, Talquetamab, Tocilizumab
- Where
- 17 sites in United States
- Volunteers
- 100 people
- Sponsor
- SCRI Development Innovations, LLC
Multiple Myeloma (MM)
A Study of WVT078 in Patients With Multiple Myeloma (MM)
The design of a phase I, open-label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent WVT078 alone and in combination with WHG626 in patients relapses and/or refractory Multiple…
- Trial name
- NCT04123418
- Testing
- WVT078, WHG626
- Where
- 12 sites in United States, Australia and 6 more
- Volunteers
- 56 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the tolerability and safety of Daratumumab in Japanese participants with relapsed (the return of a medical problem) or refractory (not responding to treatment) multiple myeloma (cancer of…
- Trial name
- NCT02116569
- Testing
- Daratumumab
- Where
- 2 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Janssen Pharmaceutical K.K.
Multiple Myeloma
Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma
Evaluation the safety,tolerability, preliminary efficacy,and PK/PD of KQ-2003 CAR-T cells for the treatment of multiple myeloma
- Trial name
- NCT04714827
- Testing
- KQ-2003 CAR-T cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanxi Province Cancer Hospital
Multiple Myeloma and Plasma Cell Neoplasm
Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00017069
- Testing
- arsenic trioxide, dexamethasone
- Where
- 10 sites in United States
- Sponsor
- CTI BioPharma
Multiple Myeloma
Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma
The purpose of this study is to find out what effects, good and/or bad, the combination of panobinostat and carfilzomib have on the patient's cancer.
- Trial name
- NCT01549431
- Testing
- Panobinostat, Carfilzomib, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Emory University
Multiple Myeloma
Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma
For each subject the study will consist of two phases: a treatment phase and a follow-up phase. Screening procedures will take place within 28 days of baseline.
- Trial name
- NCT00065351
- Testing
- CC-5013
- Where
- 26 sites in United States
- Volunteers
- 222 people
- Sponsor
- Celgene
Refractory Multiple Myeloma
Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as bendamustine hydrochloride and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01049945
- Testing
- bendamustine hydrochloride, lenalidomide, dexamethasone
- Where
- 5 sites in United States
- Volunteers
- 70 people
- Sponsor
- Mayo Clinic
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma
This phase I/II trial studies the best dose and side effects of venetoclax and how well it works in combination with ixazomib and dexamethasone in treating patients with t(11;14) negative multiple myeloma that has come back or…
- Conditions
- Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, t(11;14) Negative
- Trial name
- NCT03856112
- Testing
- Dexamethasone, Ixazomib, Ixazomib Citrate
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma
The purpose of this study is to test the safety of in investigational drug called Liposomal curcumin (LipoCurc) and to find the highest dose that can be given without causing very severe side effects.
- Trial name
- NCT07456605
- Testing
- Liposomal Curcumin (LipoCurc)
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Relapsed Refractory Multiple Myeloma (RRMM)
Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)
This study will evaluate efficacy and tolerability various doses of belantamab mafodotin in combination with cevostamab and pomalidomide in patients with multiple myeloma who have relapsed disease after two or more lines of…
- Trial name
- NCT07831122
- Testing
- Belamaf, Cevostamab, Pomalidomide
- Where
- 7 sites in Canada
- Volunteers
- 108 people
- Sponsor
- Canadian Myeloma Research Group
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma
This phase I trial tests the side effects and best dose of TGFbi natural killer (NK) cells (TiNK) when given together with isatuximab for the treatment of patients with multiple myeloma that has come back after a period of…
- Trial name
- NCT06203912
- Testing
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Cyclophosphamide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Elvira Umyarova
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells
This phase 1, open-label, single-arm, prospective, single center study will evaluate the safety, tolerability and efficacy of cyclosporine in combination with carfilzomib and dexamethasone in patients with relapsed and refractory…
- Trial name
- NCT04813653
- Testing
- cyclosporine in combination with carfilzomib and dexamethasone
- Where
- Israel
- Volunteers
- 3 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Lymphoma, Refractory B-Cell Lymphoma
Study of CAR-T Therapy in Older Patients
This study is being done to find out how older patients respond to CAR-T cell therapy and how the treatment affects their quality of life.
- Conditions
- Lymphoma, Refractory B-Cell Lymphoma, Lymphoma, B-Cell, DLBCL NOS
- Trial name
- NCT04300998
- Testing
- Activities of Daily Living/ADLs, Instrumental Activity of Daily Living, Timed Up and Go
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- Memorial Sloan Kettering Cancer Center